Medical Advocates
Pegylated Interferons
    Hepatitis C

Peg Interferon Alfa 2a
Peg Interferon Alfa 2b
General Reports
Efficacy Studies
 Adverse Events
Quality of Life
 Adherence


 

  
Peg Interferons Main Page Main New/Newsworthy Home Page

Last Update:  August 27, 2008
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

General Reports
     
     Journal Papers, Abstracts, and Commentaries
 
 
FULL-TEXT PDF ARTICLE
 Suitable treatment period in patients with virological response during combination therapy of peginterferon and ribavirin
for chronic hepatitis C.
 Arase Y, Suzuki F, Sezaki H, et al
Intern Med. 2008;47(14):1301-7.
 Paper
 
Chronic Hepatitis C Virus Genotype 6 Infection: Response to Pegylated Interferon and Ribavirin.
 Fung J, Lai CL, Hung I, et al  
J Infect Dis. 2008 Jul 25.
 Abstract
 
Optimal dose of peginterferon and ribavirin for treatment of chronic hepatitis C.
 Gambarin-Gelwan M, Jacobson IM.
J Viral Hepat. 2008 Jul 10.
 Abstract
 
Peginterferon vs. interferon in the treatment of different HCV genotype infections in HIV patients.
Zhao S, Cheng D, Liu E, et al
Eur J Clin Microbiol Infect Dis. 2008 Jun 17.
Abstract
 
Do thyroid abnormalities detected in patients treated for HCV-related chronic hepatitis persist?
 Tarantino G, Gagliardi G, Conca P.  
Int J Immunopathol Pharmacol. 2008 Apr-Jun;21(2):467-9.
 Abstract
 
Early and Accurate Prediction of Peg-IFNs/Ribavirin Therapy Outcome in the Individual Patient
With Chronic Hepatitis C by Modeling the Dynamics of the Infected Cells.
Colombatto P, Ciccorossi P, Maina A, et al
Clin Pharmacol Ther. 2008 Mar 12
 Abstract
 
Pegylated interferon therapy in chronic hepatitis C: lights and shadows of an innovative
treatment.
Almasio PL, Cottone C, D'Angelo F.
Dig Liver Dis. 2007 Sep;39 Suppl 1:S88-95.
Abstract
 
Mutations in the interferon sensitivity determining region (NS5A aa 2209-2248) in patients with
hepatitis C 1b infection and correlating response to combined therapy of pegylated interferon
and ribavirin.
 Yen YH, Hung CH, Hu TH, et al  
 Aliment Pharmacol Ther. 2007 Oct 26;
 Abstract
 
Haematological support during peg-interferon therapy for HCV-infected haemophiliacs improves
virological outcomes.
Kevans D, Farrell G, Hopkins S, et al
 Haemophilia. 2007 Sep;13(5):593-598.
Abstract 
 
Infant of 22 months of age with no anomalies born from a HCV- and HIV-infected mother
under treatment with pegylated interferon, ribavirin and antiretroviral therapy during the first
16 weeks of pregnancy.
 Labarga P, Pinilla J, Cachorro I, Del Prado YR.
 Reprod Toxicol. 2007 Jul 7;
Abstract 
 
Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic
hepatitis C: a systematic review and economic evaluation.
 Shepherd J, Jones J, Hartwell D, et al
 Health Technol Assess. 2007 Mar;11(11):1-224
 Abstract
 
Emerging strategies for pegylated interferon combination therapy.
 Schiff ER.  
Nat Clin Pract Gastroenterol Hepatol. 2007 Jan;4 Suppl 1:S17-21.
 Abstract
 
Pegylated interferon plus ribavirin for chronic hepatitis C: the role of combination therapy today,
tomorrow and in the future.
Ferenci P.
Minerva Gastroenterol Dietol. 2006 Jun;52(2):157-74
 Abstract 
 
Impact of double-filtration plasmapheresis in combination with interferon and ribavirin in living
donor liver transplant recipients with hepatitis C.
Taniguchi M, Furukawa H, Shimamura T, et al
Transplantation. 2006 Jun 27;81(12):1747-9.
 Abstract

Pegylation of interferon alfa: structural and pharmacokinetic properties.
Pedder SC.
Semin Liver Dis. 2003;23 Suppl 1:19-22
 Abstract

     Conference Reports, Abstracts, and Posters 

  Anti golgi complex antibodies during pegylated interferon therapy for hepatitis c:
what does it mean?
Paraná R., Schinoni M., Codes L, et al
 (12th International Symposium on Viral Hepatitis and Liver Disease)
 Abstract
Viral Dynamics
     

Peg Interferons/Ribavirin

     Journal Papers, Abstracts, and Commentaries

  Predictors of viral kinetics to peginterferon plus ribavirin combination therapy
in Japanese patients infected with hepatitis C virus genotype 1b.
 Akuta N, Suzuki F, Kawamura Y, et al
 J Med Virol. 2007 Nov;79(11):1686-95.
Abstract
Diagnostics
     

     Journal Papers, Abstracts, and Commentaries

  Predicting sustained virological response in chronic hepatitis C patients treated with
pegylated interferon and ribavirin using a novel highly sensitive Real-time detection
PCR assay
 Matsuura K, Tanaka Y, Takagi K,
Rinsho Byori. 2007 Nov;55(11):983-8
 Abstract
Efficacy (General Reports)
     
Peg Interferon Monotherapy
 
     Journal Papers, Abstracts, and Commentaries
 
  Pegylated interferon treatment of acute pericarditis associated with acute hepatitis C.
Kocaman O, Aygün C, Konduk T, et al
Turk J Gastroenterol. 2007 Dec;18(4):268-271.
 Abstract 
 
Peg Interferon/Ribavirin
 
     Journal Papers, Abstracts, and Commentaries
 
 
Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C
due to genotype 4.
 Martín-Carbonero L, Puoti M, et al
 J Viral Hepat. 2008 Jul 10.
 Abstract|
 
Effectiveness of the combined interferon and ribavirin therapy in hepatitis C virus infection in patient
with hypertension and kidney function disorder.
 Bátyi E, Szegedi J.
Orv Hetil. 2008 May 8;149(19):889-92.
 Abstract 
 
Results of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in
clinical practice: a 5-year experience.
 Vergara M, Gallach M, Dalmau B, et al 
Gastroenterol Hepatol. 2008 May;31(5):274-9.
 Abstract 

Efficacy in Patients with Dose Reduction in Combination Therapy of Peginterferon and Ribavirin
for Chronic Hepatitis C.
 Arase Y, Suzuki F, Sezaki H 
Intervirology. 2008 Feb 29;51(1):1-6
Abstract 
 
Eicosapentaenoic Acid Could Permit Maintenance of the Original Ribavirin Dose in Chronic
Hepatitis C Virus Patients during the First 12 Weeks of Combination Therapy with
Pegylated Interferon-alpha and Ribavirin. A Prospective Randomized Controlled Trial.
Takaki S, Kawakami Y, Imamura M, Aikata  
Intervirology. 2008 Feb 4;50(6):439-446 [
 Abstract 
 
Baseline CD4 Cell Count and Outcome of Pegylated Interferon Plus Ribavirin Therapy in
HIV/Hepatitis C Virus-Coinfected Patients.
 Valerio L, Yazdanpanah Y, Poizot-Martin I, et al
 J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):50-55.
Abstract 
 
Treatment of acute hepatitis C in an HIV-positive man with pegylated interferon and ribavirin
for 24 weeks.
Rafiq N, Carriero D, Uriel A, Dieterich DT.
AIDS Read. 2007 Nov;17(11):561-4.
 Abstract 
 
Treatment With Pegylated Interferon and Ribavirin for Hepatitis C Virus-associated Severe
Cryoglobulinemia in a Liver/Kidney Transplant Recipient.
 Montalbano M, Pasulo L, Sonzogni A, et al
 J Clin Gastroenterol. 2007 Feb;41(2):216-220.
 Abstract 
 
Pegylated Interferon and Ribavirin Failures: Is Retreatment an Option?
 Cheruvattath R, Rosati MJ, Gautam M, et al  
Dig Dis Sci. 2007 Jan 26;
Abstract 
 
Treatment of chronic hepatitis C in non-responsive patients with pegylated interferon associated
with ribavirin and thalidomide: report of six cases of total remission.
 Caseiro MM.  
Rev Inst Med Trop Sao Paulo. 2006 Mar-Apr;48(2):109-12.
Abstract 
 
Sustained virologic response with short-course ribavirin and peginterferon treatment in 2 patients
coinfected with HIV and HCV genotype 1.
 Patel MR, Mullen MP, Dieterich DT. et al 
AIDS Read. 2006 Mar;16(3):164, 168-9;
 Abstract 
 
Sustained virological response rate to pegylated interferon plus ribavirin for chronic hepatitis C
in African Americans: results in treatment-naive patients in a university liver clinic.
 Srivastava S, Bertagnolli M, Lewis JH.   
J Natl Med Assoc. 2005 Dec;97(12):1703-7.
 Abstract 
 
Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection.
 Legrand-Abravanel F, Nicot F ,Boulestin A, et al
 J Med Virol. 2005 Sep;77(1):66-9.
 Abstract 

Treatment of chronic hepatitis C infection with peginterferons plus ribavirin.
 Fried MW, Hadziyannis SJ.
Semin Liver Dis. 2004 May;24 Suppl 2:47-54.
Abstract 

Current status of the use of growth factors and other adjuvant medications in patients
receiving peginterferon and ribavirin.
Kontorinis N, Agarwal K, Dieterich DT. et al
 Rev Gastroenterol Disord. 2004;4 Suppl 1:S39-47
 Abstract
 
     Conference Reports, Abstracts, and Posters 
 
 
Long-term outcomes after peg-IFN plus ribavirin in HIV/HCV-cirrhotic patients with hypersplenism undergoing
partial splenic embolization (PSE)
 A. Moreno, R. Bárcena, C. Quereda
(XVII International AIDS Conference)
 Abstract
 
HCV relapses upon completion of peg-interferon plus ribavirin in HIV-infected patients: rate,
 timing and predictors
 P. Barreiro, M. Nuñez, I. Santos, et al
(XVII International AIDS Conference)
 Abstract
 
POSTER
Rapid Virological Response at Week 4 Predicts Sustained Response to Pegylated
Interferon + Ribavirin among HIV/HCV-co-Infected Patients
JA Mira, B Valera-Bestard, A Arizcorreta-Yarza, et al
 PDF Poster     Abstract
 
Treatment of Spanish HIV-infected Patients with Recurrent Hepatitis C Virus after Liver
Transplantation with Pegylated Interferon + Ribavirin: Preliminary Results of the FIPSE
OLT-HIV-05 - GESIDA 45-05 Cohort Study
JM Miro, M Montejo, L Castells, et al
 (14 CROI)
 Abstract
 
aNadir CD4 Count Does Not Predict Response to Pegylated Interferon and Ribavirin in
HIV/HCV-co-infected Patients
S Hopkins. O Barry, J Turner, et al
 (13 CROI)
Abstract
 
POSTER
Effect of HIV Co-infection and Treatment with Pegylated Interferon + Ribavirin on Hepatitis C
Virus-specific Immune Responses
L Capa, V Soriano, J García-Samaniego, et al
 (13 CROI)
 PDF Poster     Abstract
 
POSTER
Predictive Value of Early Virological Response to Treatment with Interferon-base Regimens
Plus Ribavirin in HIV Patients with Chronic Hepatitis C
 M Laguno, M Larrousse, J Murillas, et al
 (13 CROI)
 PDF Poster   Abstract

Treatment combination with pegylated-interferon and ribavirin in chronic hepatitis
of HIV-HCV coinfected patients
I Santos, J P Zabaleta, D A Rodríguez-Serrano,  et al;
 (15IAC)
 Abstract
Quality of Life
     

     Journal Papers, Abstracts, and Commentaries

  Effect of pegylated interferon treatments for chronic active hepatitis C on quality of life.
Nayman Alpat S, Usluer G, Yavuz H
J Chemother. 2008 Feb;20(1):101-5. L
Abstract
Adherence
 

     Journal Papers, Abstracts, and Commentaries

  Hepatitis C patients' self-reported adherence to pegylated interferon and ribavirin.
Weiss JJ, Bhatti L, Dieterich DT, et al
Aliment Pharmacol Ther. 2008 Apr 16
Abstract

Peg Interferons Main Page Main New/Newsworthy Home Page

Pegylated Interferons
Hepatitis C